ABSTRACTS (e-)POSTER PRESENTATIONS

P2.22 Monocytosis is associated with TET2 mutations in PTCL-NOS and AITL

J. Depaus, T. Clozel, P. Gaulard, C. Haioun

P3.08 Successful renal transplantation after autologous hematopoietic stem cell transplantation in anuric multiple myeloma

A. Dermine, J. Devreux, J.P. Cosyns, P. Saussoy, L. Labriola, M. Mourad, L. Michaux, X. Poiré, V. Havelange, M-C. Vekemans

P3.07 Feasibility of analyzing BCR-ABL1 transcripts on bone marrow samples using the GeneXpert system

C. Van Laer, J. De Roover, B. Wilmsen, N. Boeckx

P3.06 Les toxidermies à l’imatinib. Etude retrospective a propos de 28 cas

S. Anoun, M. Qachouh, M. Lamchahab, S. Benchekroun

P3.05 Efficacy of azacitidine in Belgian patients: results of a real-life non-interventional, post-marketing survey

S. Meers, D. Selleslag, Y. Beguin, C. Graux, G. Bries, D. Deeren, I. Vrelust, P. Pierre, C. Ravoet, K. Theunissen, F. Trullemans, L. Noens, P. Mineur

P3.04 Screening JAK2 V617F-negative Essential Thrombocytosis Patients for Mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1

C. AL Assaf, E. Lierman, T. Devos, C. Graux, J. Billiet, P. Papadopoulos, P. Vandenberghe

P3.03 High-sensitivity multiparameter flow cytometric analysis for evaluation of bone marrow involvement in systemic mastocytosis

E. Del Biondo, P. Vandenberghe, B. Dewaele, A. Kochuyt, N. Boeckx

P3.02 Bone Marrow Stromal Cell-derived Exosomes Facilitate Multiple Myeloma Cell Survival Through Inhibition of the JNK Pathway

J. Wang, A. Hendrix, E. De Bruyne, E. Van Valckenborgh, E. Himpe, B. De Beule, O. De Wever, K. Vanderkerken, E. Menu

P3.01 SHP2 is required for hematopoietic cell transformation by FIP1L1-PDGFRA

L. Noël, F. Arts, C. Montano-Almendras, L. Cox, O. Gielen, F. Toffalini, C. Marbehant, J. Cools, J.B. Demoulin

P2.23 Amaurosis as the inaugural sign of cerebral diffuse large B cell lymphoma in a HIV-1 patient

C. Katoto, J. De Greef, S. Bailly, X. Poiré, T. Duprez, E. Van De Neste, V. Havelange, L. Michaux, M-C. Vekemans

P4.01 Zinc finger nuclease (ZFN)-mediated FANCA disruption reveals severe growth disadvantage of FANCA knockout human embryonic stem cells (hESC)

K. Vanuytsel, L. Ordovas Vidal, Q. Cai, N. Nair, R. Van Rossom, C. Verfaillie

P2.21 Post-Transplant Lymphoproliferative Disorder following solid organ transplantation

J. Dallemagne, M-C. Ngirabacu, V. De Wilde, B. Bailly, F. Benghiat, M. Maerevoet, M.F. Dehou, N. Meuleman, D. Bron

P2.20 Galectin expression in the multiple myeloma microenvironment

J. Muller, J. Caers, M. Binsfeld, S. Dubois, G. Carmeliet, Y. Beguin, R. Heusschen

P2.19 Light chain cast nephropathy in a patient with Waldenström’s macroglobulinemia

X. Galloo, C. Caron, L. Pipeleers, K. Wissing, K. Fostier, F. Trullemans, C. Tielemans, R. Schots, A. De Becker

P2.18 Responding patients show durable responses to bendamustine in double refractory multiple myeloma patients

J. Caers, M-C. Vekemans, I. Vande Broek, V. Maertens, P.H. Mineur, G. Bries, E. Vandeneste, G. Vanstraelen, K. Beel, F. Leleu, H. Demuynck, C. Scheurmans, A. Van de Velde, W. Schroyens, K.L. Wu, N. Meuleman, R. Schots, M. Delforge, C. Doyen

P2.17 The respective value of the G8 screening and the Comprehensive Geriatric Assessment (CGA) for the identification of vulnerable older patients with hematological malignancies susceptible to benefit from chemotherapy

S. Dubruille, Y. Libert, M. Roos, S. Vandenbossche, N. Meuleman, M. Maerevoet, D. Razavi, D. Bron

P2.16 Activation of invariant natural killer T cells reduces angiogenesis in the 5T33 multiple myeloma model

H. Nur, L. Rao, A. Vacca, D. Elewaut, E. Van Valckenborgh, E. De Bruyne, K. Vanderkerken, E. Menu

P2.15 Flow cytometry characterization of micro-particles from healthy and malignant blood cells

E. Crompot

P2.14 Cost-utility of granulocyte-colony stimulating factors (G-CSFS) for primary prophylaxis (PP) of chemotherapy induced febrile neutropenia (FN) in non-Hodgkin’s lymphoma patients (NHL) in Belgium

G. Verhoef, L. Somers, A. Bosly

P2.13 Management of refractory/relapsed diffuse large B-cell lymphoma (DLBCL): the gap between guidelines and real world

M. Salati, M. Cesaretti, S. Luminari, M. Federico

P4.10 Imatinib improves survival of chronic Graft-versus-Host disease by inhibiting TGF-beta and PDGF-r pathways in mice

G. Fransolet, L. Belle, J. Somja, S. Humblet-Baron, S. Dubois, P. Delvenne, Y. Beguin, F. Baron

P4.19 Extracorporeal photopheresis for treatment in hematological diseases : a single centre experience

P.H. Huynh

P4.18 A long (GT)n repeat genetic variant in the promoter region of heme oxygenase-1 is associated with severe graft-versus-host disease

V. De Wilde, C. Spilleboudt, J. Racapé, P. Lewalle, D. Bron, M. Abramowicz, A. Le Moine

P4.17 Time To Neutrophils And Platelets Recovery In Patients Transplanted With Plerixafor Mobilized Hematopoietic Stem Cells, At The Institut Jules Bordet

P.H. Huynh

P4.16 Pneumomediastinum as a complication of allogeneic bone marrow transplantation

J. Devreux, G. David, A. Dermine, V. Havelange, B. Ghaye, E. Van den Neste, L. Michaux, X. Poiré, M-C. Vekemans

P4.15 Disseminated fusariosis following induction chemotherapy for acute leukemia

S. Bailly

P4.14 Autologous stem cell transplantation for late-onset nemaline myopathy and gammopathy

J. De Greef, S. Bailly, P.D.M. Katoto, P. Van den Bergh, X. Poiré, L. Michaux, V. Havelange, M-C. Vekemans

P4.13 CMYB expression during in vitro hematopoiesis from human embryonic stem cells

S. Vanhee, K. De Mulder, Y. Van Caeneghem, S. Taveirne, N. Van Roy, B. Menten, S. Bonte, G. Verstichel, G. Goetgeluk, M. Dullaers, J. Philippé, T. Taghon, G. Leclercq, T. Kerre, B. Vandekerckhove

P4.12 A case of transplantation-associated thrombotic microangiopathy, with surprisingly suppressed ADAMTS-13 activity

I. Moors, L. Noens, T. Kerre

P4.11 Genetic correction of induced pluripotent stem cells from a Wiskott-Aldrich Syndrome patient normalizes the immune defects

Y. Van Caeneghem, R. Pourebrahimabadi, T. Laskowski, Z. Garate, A. Crane, J.C. Segovia, M. Holmes, B. Vandekerckhove, B. Davis

P2.12 An unusual presentation of cryptococcal meningitis in a patient with lymphoplasmacytic dyscrasia

F. Van Obbergh, A. Ferrant, D. Wilmes, J. Yombi, L. Knoops, M-C. Vekemans, L. Michaux

P4.09 A novel HLA-C null variant allele (C*05:XXN) generated by single nucleotide deletion and premature stop codon in exon 3

B. Cauwelier, W. Rosseel, F. Nollet, W. Schroyens, A. Gadisseur, Z. Berneman

P4.08 Disease risk index fails to predict survival after allogeneic peripheral blood stem cell transplantation (PBSCT) - Are multiple myeloma and myeloproliferative neoplasms misclassified?

S. Servais, R. Porcher, A. Xhaard, M. Robin, E. Masson, J. Larghero, P. Ribaud, N. Dhedin, G. Socie, R. Peffault de Latour

P4.07 Clinical and Immunological Predictive Factors of Late Infection Burden After Alternative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

S. Servais, L. Lengline, R. Porcher, M. Carmagnat, R. Peffault de Latour, M. Robin, F. Sicre de Fontebrune, E. Clave, G. Maki, J.M. Molina, A. Toubert, H. Moins-Teisserenc, G. Socie

P4.06 Identification of Integrin-av as an important marker of primitive hematopoietic stem cells in mouse and human

S. Khurana, S. Schouteden, A. Santamaria-Martinez, J. Huelsken, A. Lacy-Hulbert, C. Verfaillie

P4.05 High incidence of second malignancies in patients given allogeneic hematopoietic stem cell transplantation following reduced-intensity (RIC) or nonmyeloablative conditioning

F. Baron, M. Lejeune, E. Willems, L. Seidel, K. Hafraoui, S. Servais, A. Jaspers, Y. Beguin

P4.04 Allogeneic stem cell transplantation for patients with myelofibrosis: a single center experience

A. De Cuyper, R. Galot, A. Ferrant, D. Latinne, L. Knoops, L. Michaux, V. Havelange, M-C. Vekemans, C. Lambert, E. Van den Neste, X. Poiré

P4.03 Identifying novel regulators hematopoietic stem cell expansion ex vivo

J. Manesia

P4.02 The effect of multipotent adult progenitor cells on bone marrow failure in myelodysplastic syndromes

V. Roobrouck, S. Chakraborty, T. Vanwelden, K. Sels, E. Lazarri, S. Pandey, N. Boeckx, M. Delforge, C. Verfaillie

P1.04 Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines

M. Binsfeld, R. Heusschen, V. Lamour, E. Van Valckenborgh, A. Bellahcène, F. Baron, Y. Beguin, J. Caers

P1.03 Comparison of hemoglobin on RapidPoint 500 blood gas analyser (Siemens) to XE-5000 cell counter (Sysmex)

J. Jacobs, M. D’Hondt, A. Meskal, S. Vermeiren, S. Weekx, K. Ver Elst

P1.02 Acquired hemophilia: a retrospective evaluation in the Ghent University Hospital

S. Mulliez, A. Vantilborgh, E. Steel, K. Devreese

P1.01 Flow cytometric screening in patients at risk for paroxysmal nocturnal hemoglobinuria and evaluation of clone sizes: a retrospective study

M. Mukovnikova, N. Boeckx, T. Devos

P1.05 A multicentre study characterising different regimens for introducing second- or third-line anagrelide in 177 patients in France

J. Rey, J.F. Viallard, K. Keddad, J. Smith, P. Wilde, J.J. Kiladjian

P2.02 The value of SOX11 overexpression in the differential diagnosis of mantle cell lymphoma

B. Depreter, F. Nollet, S. Vermeire, B. Cauwelier, A. Van Hoof, J. Billiet

P2.11 Activating JAK1 and JAK3 mutations cooperate to confer growth signal self-sufficiency and increased resistance to JAK inhibitors in a mouse in vitro leukemia model

L. Springuel, E. Losdyck, T. Hornakova, L. Knoops, J.C. Renauld

P2.10 BRAF V600E mutation is not a disease-defining genetic event in classic hairy cell leukemia

F. Nollet, K. Boon, J. Emmerechts, S. Vermeire, R. D’Hondt, A. Van Hoof, D. Selleslag, J. Van Droogenbroeck, T. Lodewyck, J. Billiet

P2.09 Impact of minimal residual disease monitoring on therapy in Belgian childhood acute lymphoblastic leukaemia

J. Van Der Straeten, B. De Moerloose, M-F. Dresse, S. Dupont, A. Ferster, P. Philippet, A. Uyttebroeck, J. Van der Werf ten Bosch, C. Demanet, Y Benoit, M. Bakkus

P2.08 Effect of different peak integration methods on the accuracy of paraprotein quantification on serum protein electrophoresis: what is the clinical relevance?

M. Berth

P2.07 Bing-Neel syndrome: report of two cases

E. Dumoulin, B. Depreter, L. Vanopdenbosch, J. Emmerechts, F. Nollet, D. Selleslag, A. Van Hoof, J. Billiet

P2.06 Diagnosis of lymphoma in a patient under treatment with azacytidine

K. Beel, A. De Vooght, P. Zachée, P. De schouwer, M. Kockx

P2.05 Global HDAC enzymatic activity is a strong marker of poor prognosis in Chronic Lymphocytic Leukemia

M. Van Damme, E. Crompot, N. Meuleman, P. Mineur, B. Dessars, H. El Housni, D. Bron, L. Lagneaux, B. Stamatopoulos

P2.04 Immune impairments of the multiple myeloma bone-marrow mesenchymal stromal cells

T. André, M. Najar, B. Stamatopoulos, K. Pieters, O. Pradier, D. Bron, N. Meuleman, L. Lagneaux

P2.03 Immunomodulatory Drugs Restore Effector Cell Immune Functions In Myeloma Patients With Low Disease Burden After Autologous Stem Cell Transplantation

K. Fostier, J. Corthals, C. Heirman, J.L. Aerts, K. Thielemans, R. Schots, B. De Keersmaecker

P2.01 Downregulation of cellular microRNA-150 is a new prognostic factor associated with a poor prognosis in Chronic Lymphocytic Leukemia patients

B. Stamatopoulos, N. Meuleman, E. Crompot, M. Van Damme, B. Dessars, H. El Housni, P. Mineur, D. Bron, L. Lagneaux

P1.12 Chronic EBV infection resulting in a CD20 negative lymphoproliferative disorder complicated with secondary hemophagocytosis

P. Vlummens, S. Bonte, V. Van Hende, T. Kerre

P1.11 Acute myeloblastic leukemia infiltrating-T lymphocyte characterization, from bone marrow and peripheral blood

R. Rouas, M. Merimi, M. Berehab, D. Moussa-Agha, P. Lewalle, P. Martiat

P1.10 Immunomodulatory effects of Rapamycin in xenogeneic GVHD

G. Ehx, M. Hannon, S. Dubois, A. Halleux, L. Belle, P. Drion, Y. Beguin, S. Humblet-Baron, F. Baron

P1.09 Evaluation of automated white blood cell differential count in cerebrospinal fluid on the body fluid module of Sysmex XN 2000

D. Labaere, I. Geerts, M. Moens, M. Van den Driessche

P1.08 Hemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency

S. Sid, D. Dugauquier, B. De Prijck, C. Bonnet, Y. Beguin

P1.07 Jacobsen syndrome as a rare cause of neonatal thrombocytopenia

C. Chantrain, C. Berce, J.P. Stalens, F.G. Debray, P. Philippet, N. Francotte, L. Tomme

P1.06 An unusual presentation of tuberculosis

F. Trullemans, R. Mertens, M.C. Chintinne, R. Schots

ABSTRACTS ORAL PRESENTATIONS

O.3 Comparison of 2 nonmyeloablative regimens for allogeneic HCT: a phase II randomized study from the HCT committee of the BHS

F. Baron, P. Zachée, J. Maertens, T. Kerre, A. Ory, L. Seidel, C. Graux, P. Lewalle, H. Schouten, K. Theunissen, R. Schots, Y. Beguin

O.8 JAK2 V617F-Negative AND MPL W515K/L-Negative Essential Thrombocythemia: a High Resolution SNP Array Study

C. AL Assaf, E. Lierman, T. Devos, C. Graux, J. Billiet, J. Finalet Ferreiro, P. Vandenberghe

O.7 NOTCH1 c.7544–7545 delCt mutation identifies a subgroup of lymphocytic leukemia patients with poor outcome

S. Franke, C. Herens, M. Jamar, N. Mongiovi, B. De Prijck, F. Lambert

O.6 Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation

A. Jaspers, F. Baron, E. Willems, K. Hafraoui, C. Bonnet, Y. Beguin

O.5 In vivo gene expression profiling in the murine 5T33MM model identifies epigenetic-regulated genes predictive for prognosis and drug-sensitivity

K. Maes, E. De Smedt, D. Hose, E. Van Valckenborgh, E. Menu, B. Klein, K. Vanderkerken, J. Moreaux, E. De Bruyne

O.4 Functional characterization of activating mutants of the JAK3 tyrosine kinase implicated in tumoral transformation of T lymphocytes

E. Losdyck, L. Springuel, T. Hornakova, J.C. Renauld, L. Knoops

O.2 Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation

M. Binsfeld, Y. Beguin, L. Belle, E. Otjacques, M. Hannon, A. Briquet, P. Drion, B. Bogen, F. Baron, J. Caers

O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial

M. André, B. De Prijck, A. Kentos, A. Van Hoof, C. Bonnet, A. Sonet, M. Maerevoet, E. Van den Neste, A. Bosly, N. Mounier

Implementing next-generation deep-sequencing assays in diagnostic algorithms in hematological malignancies

A. Kohlmann

To BEACOPP or not to BEACOPP: That is the question

M. Federico, M. Macchia, A. Salati, M. Bellei

Breaking Pathologic Signaling in Myeloproliferative Neoplasms: Beyond JAK2 Inhibitors

S.N. Constantinescu

Practical approach of patients with mild bleeding disorders

P. de Moerloose

Old and new anticoagulants in practice

C. Hermans

Management of Sickle Cell Disease

A. Ferster